Recent News

• 03.19.2025 - Virpax Pharmaceuticals Announces Reverse Stock Split
• 03.18.2025 - Virpax Receives Positive Probudur™ Results for Dose Range Study Moves Towards Next Steps in IND
• 03.07.2025 - Virpax Looking to Use MET to Develop Intranasal COVID Vaccine
• 03.05.2025 - Virpax’s NES100 to be Presented at The Society of Toxicology by NCATS
• 02.27.2025 - Virpax Reports Positive Results in Human Study for its Molecular Envelope Technology
• 02.13.2025 - Virpax Confirms Positive Results with US Army with Probudur™ for Combat Care Study
• 01.31.2025 - Virpax’s Matthew Barnes to Present at Outsourcing in Clinical Trials Conference
• 01.30.2025 - Virpax Pharmaceuticals, Inc. Announces Closing of $6.0 Million Public Offering of Common Stock and Pre-Funded Warrants
• 01.30.2025 - Virpax Pharmaceuticals, Inc. Announces Closing of $6.0 Million Public Offering of Common Stock and Pre-Funded Warrants
• 01.28.2025 - Virpax Pharmaceuticals, Inc. Announces Pricing of $6 Million Public Offering of Common Stock and Pre-Funded Warrants

Recent Filings

• 03.17.2025 - S-1 General form for registration of securities under the Securities Act of 1933
• 03.03.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 02.06.2025 - 8-K Current report
• 02.04.2025 - 8-K Current report
• 01.30.2025 - EX-99.1 EX-99.1
• 01.30.2025 - 8-K Current report
• 01.28.2025 - 424B4 Prospectus [Rule 424(b)(4)]
• 01.27.2025 - EFFECT Notice of Effectiveness